PMV Pharmaceuticals, Inc.
PMVP
|
$1.61
0.63%
0.62%
280K
|
Commercial Services
(0.0% 1d) (-4.7% 1m) (-65.6% 1y) (0.0% 2d) (0.6% 3d) (-10.1% 7d) (-16.11% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 82,824,016
http://www.pmvpharma.com
Sec Filling | Patents | 36 employees
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in New Jersey, NY.
cancer molecule drugs treatment
add to watch list Paper trade email alert is off
Press-releases
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: -1.2%
H: 4.27%
C: 0.61%
tp53 first tumors pharmaceuticals global trial
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: 5.99%
H: 1.13%
C: -4.52%
presentation cancer pharmaceuticals meeting advanced
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: -2.7%
H: 17.22%
C: 4.17%
year pharmaceuticals financial results
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: 1.8%
H: 7.35%
C: 5.88%
conference health care pharmaceuticals
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: 1.67%
H: 0.0%
C: -12.02%
pc1458 pharmaceuticals
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
Published: 2024-01-05 (Crawled : 21:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
| Email alert
Add to watchlist
company pharmaceuticals
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: -0.54%
H: 9.19%
C: 2.7%
pharmaceuticals financial results
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Published: 2023-10-12 (Crawled : 17:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: 0.63%
H: 1.88%
C: -47.91%
pc1458 pharmaceuticals tumor tp53
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
Published: 2023-10-11 (Crawled : 17:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: 0.47%
H: 1.49%
C: -26.36%
pc1458 conference cancer international pharmaceuticals therapeutics molecular
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-09-20 (Crawled : 20:00) - globenewswire.com
PMVP | $1.61 0.63% 0.62% 280K
|
Commercial Services
|
| O: -1.06%
H: 5.05%
C: 2.52%
pc1458 conference cancer international pharmaceuticals therapeutics molecular
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Last 48 Hours Insiders Buying
IZEA | $2.5 -2.4% 8.6K
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 1.05% 1.4M
|
Finance
|
22:30
CTRN P 18090 | $22.46 -1.01% -1.02% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.795 2.38% 0.18% 35K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 3.1M
|
Health Technology
|
16:30
RMCF | $3.51 -3.7% -3.85% 3.8K
|
Consumer Non-Durables
|
20:10